Key insights
- Pfizer warns shareholders against a mini-tender offer from Tutanota LLC to purchase up to 1 million shares at $32.00 per share, which is conditional on Pfizer's stock price exceeding $32.00. Pfizer recommends shareholders not to tender their shares due to the below-market pricing condition and other uncertainties. The offer represents a small fraction of outstanding shares and is viewed as potentially misleading to investors.
NEW YORK - Pfizer Inc. (NYSE:PFE) disclosed that Tutanota LLC has made an unsolicited mini-tender offer to purchase up to 1 million shares of Pfizer common stock at $32.00 per share, according to a company statement.
The offer price is conditioned on Pfizer’s closing stock price exceeding $32.00 per share on the last trading day before the offer expires, meaning shareholders who tender their shares would receive a below-market price unless the condition is waived. Pfizer shares currently trade at $26.99, well below the $32 offer threshold. According to InvestingPro analysis, the stock appears undervalued with a Fair Value of $31.15, suggesting potential upside for patient investors who hold rather than tender. The offer represents approximately 0.02% of Pfizer’s outstanding shares as of March 9.
Pfizer recommends shareholders not tender their shares, citing the below-market pricing condition and numerous additional conditions, including Tutanota’s need to obtain financing, which the company states it does not currently have. The offer is scheduled to expire at 5:00 p.m. New York time on April 13, 2026, though Tutanota can extend this deadline.
Shareholders who have tendered shares can withdraw them prior to the expiration date in accordance with the offering documents.
Pfizer stated it does not endorse the offer and has no affiliation with Tutanota. The company noted that Tutanota has made similar mini-tender offers for shares of other companies. Investors seeking deeper analysis can access Pfizer’s comprehensive Pro Research Report, available for this and 1,400+ other US equities.
Mini-tender offers seek to acquire less than 5% of a company’s shares, avoiding many disclosure and procedural requirements of the U.S. Securities and Exchange Commission that apply to larger tender offers. The SEC has cautioned investors that some bidders making mini-tender offers at below-market prices may catch investors off guard if they fail to compare the offer price to current market prices.
Pfizer urged investors to obtain current market quotations, consult with brokers or financial advisors, and exercise caution regarding the offer.
In other recent news, Pfizer Inc. announced that its Phase 2 FOURLIGHT-1 study showed promising results for its breast cancer drug candidate, atirmociclib. The study demonstrated a 40% reduction in the risk of disease progression or death when atirmociclib was combined with fulvestrant, compared to other treatments. This trial included 264 patients across 14 countries, marking a statistically significant improvement in progression-free survival. Meanwhile, Pfizer’s investigational drug tilrekimig also met its primary endpoint in a Phase 2 study for atopic dermatitis, showing a significant increase in participants achieving a 75% reduction in symptoms at Week 16 compared to a placebo.
Morgan Stanley maintained an Equalweight rating on Pfizer, with a price target of $27.00, following the positive trial data for atirmociclib. BMO Capital reiterated an Outperform rating with a $30.00 price target after reviewing Phase 2 data for tilrekimig. The tri-specific antibody demonstrated notable efficacy in easing symptoms of atopic dermatitis, achieving a placebo-adjusted high of 51.9% improvement in the middle dose group. These developments highlight Pfizer’s ongoing efforts in advancing treatments for cancer and skin conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.